<DOC>
	<DOCNO>NCT02501356</DOCNO>
	<brief_summary>To compare effect daily intake ISOThrive supplement vs. placebo primary outcome measure body weight secondary outcome measure ( hunger/satiety , health-related measure self-reported quality life ) group overweight otherwise healthy adult .</brief_summary>
	<brief_title>Effects ISOThrive Bodyweight , Body Composition , Hunger/Satiety Cardiac Risk Measures Overweight Adults</brief_title>
	<detailed_description>Hypothesis The investigator 's hypothesize daily intake 3-month period ISOThrive supplement vs. placebo demonstrate beneficial effect primary outcome measure body weight secondary outcome measure ( hunger/satiety , health-related measure self-reported quality life ) group overweight adult . Specific Aims - To determine effect ISOThrive supplement body weight overweight adult encourage reduce calorie exercise regularly , unrestricted diet without specific exercise instruction . Specifically , demonstrate clinically meaningful reduction body weight group overweight adult 3 month daily consumption ISOThrive supplement . - To determine effect ISOThrive supplement hunger/satiety , body composition , waist circumference , blood pressure , blood glucose level , blood lipid level , inflammatory satiety serum marker self-reported quality life overweight adult encourage reduce calorie exercise regularly , unrestricted diet without specific exercise instruction . Specifically , demonstrate improvement hunger/satiety clinically meaningful improvement measure group overweight adult 3 month daily consumption ISOThrive supplement . - To demonstrate safety ISOThrive supplement term impact blood , liver kidney function overweight adult . Specifically , demonstrate lack negative impact blood , liver kidney function test group overweight adult 3 month daily consumption ISOThrive supplement . - To determine effect ISOThrive supplement Gut health . Specifically , demonstrate improvement Gut health measure abdominal bloating , abdominal gas , abdominal pain/discomfort end 3 month daily consumption ISOThrive supplement .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<criteria>BMI 25 weight &gt; 350lb Age 18 75 Nonsmokers Able read write English Pregnant and/or lactate woman Evidence history substance alcohol abuse ( include 5years ) History major depression , bipolar disorder schizophrenia , type obsessivecompulsive disorder Current history migraine headache ( include control medication ) Current use prescription nonprescription weight loss product Tobacco use Active eating disorder include anorexia nervosa bulimia Known sensitivity allergy ingredient product Symptomatic coronary artery disease congestive heart failure History stroke past year Symptomatic arrhythmia Uncontrolled hypertension ( i.e . systolic pressure &gt; 180 mmHg diastolic &gt; 110 mmHg ) History seizure past 5 year Any cancer past 5 year nonmelanoma skin cancer insitu cervical cancer Active history inflammatory bowel disease Current use TNFalpha inhibitor medication Current use COX2 inhibitor medication Current use JAK inhibitor medication History weight loss procedure include bariatric surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>prebiotic</keyword>
	<keyword>dietary supplement</keyword>
</DOC>